Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B.

It has undergone Phase I clinical trials in 2001.

[1][2] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.